Literature DB >> 10869055

T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy.

J Schmidt1, R Gold, L Schönrock, U K Zettl, H P Hartung, K V Toyka.   

Abstract

The apoptosis-inducing effects of i.v. methylprednisolone were investigated as a possible method of controlling inflammation in the CNS in adoptive transfer-experimental autoimmune encephalomyelitis (AT-EAE) in Lewis rats. Two pulses of methylprednisolone were given at the peak of mild and of severe disease. T-cell apoptosis was assessed on spinal cord cross-sections by morphology and TUNEL staining. Concentrations of methylprednisolone were measured in serum, CSF and spinal cord tissue by high-pressure liquid chromatography (HPLC). In severe EAE, 10 mg/kg methylprednisolone increased T-cell apoptosis significantly and T-cell infiltration was marginally decreased. A maximal dose of 50 mg/kg methylprednisolone was superior in both respects and, in contrast to 10 mg/kg methylprednisolone, was also effective in mild EAE. A dose of 1 mg/kg methylprednisolone did not produce notable changes compared with controls treated with phosphate-buffered saline. Serum, CSF and spinal cord concentrations of methylprednisolone measured by HPLC 2 h after a single i.v. injection of 10 or 50 mg/kg methylprednisolone revealed significantly higher methylprednisolone concentrations in severe EAE compared with mild disease. With 50 mg/kg methylprednisolone, we obtained serum and CSF concentrations in the region of 10(-5) M methylprednisolone. We also studied the expression of bcl-2, a typical anti-apoptotic regulatory protein, in T cells, and found no change after methylprednisolone treatment compared with controls. Methylprednisolone did not induce apoptosis of oligodendrocytes, which would have been an unwanted side effect in CNS cells. This study provides evidence that methylprednisolone dose-dependently augments T-cell apoptosisin situ in AT-EAE. Our results may have implications for the use of glucocorticosteroids at very high doses in the treatment of inflammatory disorders of the CNS, such as multiple sclerosis, or of other target organs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869055     DOI: 10.1093/brain/123.7.1431

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

Review 1.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

2.  Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation.

Authors:  G Meneses; G Gevorkian; A Florentino; M A Bautista; A Espinosa; G Acero; G Díaz; A Fleury; I N Pérez Osorio; A Del Rey; G Fragoso; E Sciutto; H Besedovsky
Journal:  Clin Exp Immunol       Date:  2017-09-07       Impact factor: 4.330

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Authors:  A Chan; F X Weilbach; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

5.  Bioavailability effect of methylprednisolone by polymeric micelles.

Authors:  Ching-Lin Chen; Shwu-Fen Chang; Daniel Lee; Lang-Yo Yang; Yi-Hsuan Lee; Chung Y Hsu; Shwu-Jiuan Lin; Jiahorng Liaw
Journal:  Pharm Res       Date:  2007-11-08       Impact factor: 4.200

6.  Microglia polarization by methylprednizolone acetate accelerates cuprizone induced demyelination.

Authors:  Golaleh Noorzehi; Parichehr Pasbakhsh; Maryam Borhani-Haghighi; Iraj Ragerdi Kashani; Soheila Madadi; Fatemeh Tahmasebi; Saied Nekoonam; Maryam Azizi
Journal:  J Mol Histol       Date:  2018-08-24       Impact factor: 2.611

7.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  [Steroids for optic nerve diseases?].

Authors:  W A Lagrèze
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

Review 9.  Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Authors:  Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 10.  Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.

Authors:  Hayrettin Tumani; Ingo Uttner
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.